Core Viewpoint - Company Kubo Medical-B (02216) plans to acquire 157,800 shares of Series B preferred stock of Valgen Holding Corporation for $15 million, representing 1.05% of the target company's fully diluted shares as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made through Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation specializes in providing systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly™ mitral valve repair device and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases, given the similarities and connections between structural heart diseases and pulmonary diseases [1] - The collaboration is expected to leverage the company's expertise in chronic obstructive pulmonary disease (COPD) to strengthen the foundation for a comprehensive cardiopulmonary diagnostic and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities by applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]

Core Viewpoint - Company Kubo Medical-B (02216) announced the acquisition of 157,800 shares of Series B preferred stock in Valgen Holding Corporation for a total consideration of $15 million, representing 1.05% of the target company's fully diluted and converted shares outstanding as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made by Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation primarily provides systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly mitral valve repair device (via the transvenous approach) and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity for the company to achieve comprehensive diagnosis and treatment of cardiopulmonary diseases, given the similarities and correlations between structural heart diseases and pulmonary diseases [1] - The collaboration with Valgen will leverage the company's expertise in chronic obstructive pulmonary disease to establish a solid foundation for a comprehensive cardiopulmonary diagnosis and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities, applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]

Core Viewpoint - The acquisition of a 1.05% stake in Valgen Holding Corporation by Broncus China Holding Corporation for $15 million (approximately HKD 117 million) is seen as a strategic move to enhance the company's capabilities in comprehensive diagnosis and treatment of cardiopulmonary diseases [1]. Group 1: Acquisition Details - Broncus China Holding Corporation, a wholly-owned subsidiary of the company, has entered into a share transfer agreement with Qi Ming Medical (Hong Kong) Limited to acquire shares in Valgen Holding Corporation [1]. - The total consideration for the acquisition is $15 million, equivalent to approximately HKD 117 million [1]. - Valgen Holding Corporation is registered in the Cayman Islands and focuses on providing systemic solutions for mitral and tricuspid regurgitation diseases [1]. Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to achieve a comprehensive diagnosis and treatment platform for cardiopulmonary diseases [1]. - The company's expertise in chronic obstructive pulmonary disease (COPD) will complement the target group's offerings, facilitating the establishment of a robust foundation for integrated cardiopulmonary disease management [1].